What is compounded semaglutide and is it safe? The weight loss drugs Hims & Hers is selling, explained.
"They’re priced for profits, not patients.” That’s the critique from Hims & Hers Health’s buzzy — and controversial — Super Bowl ad, leveling the accusation against brand-name weight loss drugs. Set ...
What is compounded semaglutide and is it safe? The more affordable weight loss drugs Hims & Hers is selling, explained.
Compounded semaglutide is legal, but it's not regulated in the same way as medications like Ozempic and Wegovy.
The Schall Law Firm Invites Shareholders With Losses To Join A Securities Fraud Case Against Novo Nordisk A/S
LOS ANGELES, CA / ACCESS Newswire / February 8, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a ...
Is the promise of more affordable weight loss drugs too good to be true? Compounded semaglutide, explained.
Compounded semaglutide is legal, but it's not regulated in the same way as medications like Ozempic and Wegovy.
Hims & Hers faces scrutiny from lawmakers over ‘misleading' Super Bowl ad
Two U.S. senators wrote a letter to the Food and Drug Administration on Friday expressing concerns about an upcoming Super ...
Ozempic Could Get Way Too Expensive Under Trump—Here's What You Can Do
While it may seem strange that politics could impact the price of popular weight loss drugs, it is a definite possibility.
Biotech in B.C. battles harsh market while landing big deals
Days after Vancouver’s Aspect Biosystems Ltd. landed US$115 million in Series B financing in early January, CEO Tamer Mohamed likely surprised many by telling BIV that he thought the investment ...
Hims & Hers faces scrutiny from senators on Super Bowl ad that ‘risks misleading' patients
Two U.S. senators wrote a letter to the Food and Drug Administration on Friday expressing concerns about an upcoming Super ...
Hims & Hers Health down as Super Bowl ad draws controversy
An advocacy group criticizes Hims & Hers Health for allegedly misleading Super Bowl ad promoting weight loss products, violating FDA regulations. Read more here.
Eli Lilly to release late-stage data on next-generation weight loss drug retatrutide in 2025, earlier than expected
Eli Lilly expects to read out results from a study in people with obesity and osteoarthritis of the knee in 2025.
Novo Nordisk CEO says he's confident about Wegovy supply, next-generation weight loss drugs
Ozempic and Wegovy maker Novo Nordisk quieted Wall Street’s concerns with its fourth-quarter results and 2025 outlook.